Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and acceptably safe for the treatment of type 2 diabetes and obesity, leading to ...
A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...
Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback